blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4410315

EP4410315 - ANTI-CD3 ANTIBODIES AND METHODS OF USE [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  14.05.2025
Database last updated on 09.04.2026
FormerThe application has been published
Status updated on  05.07.2024
Most recent event   Tooltip18.12.2025New entry: Renewal fee paid 
Applicant(s)For all designated states
GENENTECH, INC.
1 DNA Way
South San Francisco, CA 94080-4990 / US
[2024/32]
Inventor(s)01 / CHEN, Xiaocheng
South San Francisco, 94080-4990 / US
02 / DENNIS, Mark S.
San Carlos, 94070 / US
03 / EBENS, Allen J. Jr
San Carlos, 94070 / US
04 / JUNTTILA, Teemu T.
South San Francisco, 94080-4990 / US
05 / KELLEY, Robert F.
South San Francisco, 94080-4990 / US
06 / MATHIEU, Mary A.
South San Francisco, 94080-4990 / US
07 / SUN, Liping L.
South San Francisco, 94080-4990 / US
 [2024/32]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2024/32]
Application number, filing date24170644.917.12.2014
[2024/32]
Priority number, dateUS201361917346P17.12.2013         Original published format: US 201361917346 P
US201461949950P07.03.2014         Original published format: US 201461949950 P
US201462026594P18.07.2014         Original published format: US 201462026594 P
US201462053582P22.09.2014         Original published format: US 201462053582 P
US201462091441P12.12.2014         Original published format: US 201462091441 P
[2024/32]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP4410315
Date:07.08.2024
Language:EN
[2024/32]
Type: A3 Search report 
No.:EP4410315
Date:30.10.2024
Language:EN
[2024/44]
Search report(s)(Supplementary) European search report - dispatched on:EP30.09.2024
ClassificationIPC:C07K16/28, C07K16/30, C07K16/32, A61K39/395, A61P35/00, A61P37/00
[2024/44]
CPC:
C07K16/32 (EP,IL,US); C07K16/2809 (EP,IL,KR,US); A61K31/573 (EP,IL,US);
A61K39/39558 (IL,US); A61K45/06 (IL,US); A61K47/6881 (EP,IL,US);
A61P1/04 (EP); A61P13/12 (EP); A61P17/00 (EP);
A61P17/06 (EP); A61P19/02 (EP); A61P21/04 (EP);
A61P25/00 (EP); A61P25/02 (EP); A61P27/02 (EP);
A61P29/00 (EP); A61P3/10 (EP); A61P35/00 (EP,KR);
A61P35/02 (EP); A61P37/00 (EP); A61P37/02 (EP);
A61P37/04 (EP); A61P37/06 (EP); A61P43/00 (EP);
A61P7/00 (EP); A61P7/04 (EP); A61P9/00 (EP);
A61P9/08 (EP); C07K16/2827 (EP,IL,US); C07K16/283 (EP,IL,US);
C07K16/2863 (IL,US); C07K16/2887 (EP,IL,US); C07K16/2896 (IL,US);
C07K16/30 (EP,IL,US); A61K2039/505 (EP,KR,US); C07K2317/21 (IL,US);
C07K2317/24 (EP,US); C07K2317/31 (EP,IL,KR,US); C07K2317/33 (EP,IL,US);
C07K2317/34 (EP,IL,US); C07K2317/522 (US); C07K2317/524 (IL,US);
C07K2317/526 (US); C07K2317/54 (IL,US); C07K2317/55 (IL,US);
C07K2317/56 (IL,US); C07K2317/622 (US); C07K2317/71 (IL,US);
C07K2317/73 (EP,IL,KR,US); C07K2317/92 (EP,US) (-)
Former IPC [2024/32]A61K47/68
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/32]
Extension statesBA29.04.2025
ME29.04.2025
TitleGerman:ANTI-CD3-ANTIKÖRPER UND VERFAHREN ZUR VERWENDUNG[2024/32]
English:ANTI-CD3 ANTIBODIES AND METHODS OF USE[2024/32]
French:ANTICORPS ANTI-CD3 ET PROCÉDÉS D'UTILISATION[2024/32]
Examination procedure29.04.2025Amendment by applicant (claims and/or description)
29.04.2025Examination requested  [2025/23]
29.04.2025Date on which the examining division has become responsible
Parent application(s)   TooltipEP14828608.1  / EP3083689
EP20170466.5  / EP3736292
Fees paidRenewal fee
16.04.2024Renewal fee patent year 03
16.04.2024Renewal fee patent year 04
16.04.2024Renewal fee patent year 05
16.04.2024Renewal fee patent year 06
16.04.2024Renewal fee patent year 07
16.04.2024Renewal fee patent year 08
16.04.2024Renewal fee patent year 09
16.04.2024Renewal fee patent year 10
19.12.2024Renewal fee patent year 11
17.12.2025Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A] WO2012162067  (MACROGENICS INC et al.)
 [A] WO2008119566  (MICROMET AG et al.)
 [A] WO2011143545  (RINAT NEUROSCIENCE CORP et al.)
 [A] WO2007146968  (TRUBION PHARMACEUTICALS et al.)
 [A] US2013129723  (BLANKENSHIP JOHN W et al.)
 [AP]   JASON R WESTIN ET AL: "Safety and Activity of PD1 Blockade by Pidilizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: a Single Group, Open-label, Phase 2 Trial", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 15, no. 1, 1 January 2014 (2014-01-01), pages 69 - 77, XP002737602, DOI: 10.1016/S1470-2045(13)70551-5

DOI:   http://dx.doi.org/10.1016/S1470-2045(13)70551-5
by applicantUS6075181
 US6150584
 WO9316185
 US5571894
 US5587458
 US5869046
 EP0404097
 WO9301161
 US6248516
 US4816567
 US5821337
 US7527791
 US6982321
 US7087409
 US5770429
 US7041870
 US2007061900
 US7189826
 US5750373
 US2005079574
 US2005119455
 US2005266000
 US2007117126
 US2007160598
 US2007237764
 US2007292936
 US2009002360
 US2010111856
 US7799900
   FOOTEWINTER, JMB, vol. 224, 1992, pages 487
   PADLAN ET AL., MOL. IMMUNOL., vol. 31, 1994, pages 169
   NICOLAOU ET AL., ANGEW. CHEM INTI. ED. ENGL., vol. 33, 1994, pages 183 - 186
   HOOGENBOOMWINTER, J. MOL. BIOL., vol. 222, 1991, pages 581
   MURAKAMI ET AL.: "The Molecular Basis of Cancer", 1995, W.B. SAUNDERS, article "Cell cycle regulation, oncogenes, and antineoplastic drugs", pages: 13
   COLE ET AL.: "Monoclonal Antibodies and Cancer Therapy", 1985, ALAN R. LISS, pages: 77
   BOERNER ET AL., J. IMMUNOL., vol. 147, no. 1, 1991, pages 86 - 95
   VAN DIJKVAN DE WINKEL, CURR. OPIN. PHARMACOL., vol. 5, 2001, pages 368 - 74
   LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562
   KABAT ET AL.: "Sequences of Proteins of Immunological Interest", NIH PUBLICATION 91-3242, vol. 1-3, 1991
   CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
   MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
   FLATMAN ET AL., J. CHROMATOGR., vol. B848, 2007, pages 79 - 87
   KINDT ET AL.: "Kuby Immunology", 2007, W.H. FREEMAN AND CO., pages: 91
   PORTOLANO ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623 - 887
   CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
   CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881
   PRESTA ET AL., CANCER RES., vol. 57, 1997, pages 4593 - 4599
   HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134
   WINTER ET AL., ANN. REV. IMMUNOL., vol. 113, 1994, pages 433 - 455
   HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
   MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
   ALMAGROFRANSSON, FRONT. BIOSCI., vol. 13, 2008, pages 1619 - 1633
   RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
   QUEEN ET AL., PROC. NATL ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033
   DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 61 - 68
   KLIMKA ET AL., BR. J. CANCER, vol. 83, 2000, pages 252 - 260
   CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285
   BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684
   ROSOK ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 22611 - 22618
   LONBERG, CURR. OPIN. IMMUNOL., vol. 20, 2008, pages 450 - 459
   LONBERG, NAT. BIOTECH., vol. 23, 2005, pages 1117 - 1125
   KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001
   BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 51 - 63
   NI, XIANDAIMIANYIXUE, vol. 26, no. 4, 2006, pages 265 - 268
   VOLLMERSBRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, vol. 20, no. 3, 2005, pages 927 - 937
   VOLLMERSBRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 27, no. 3, 2005, pages 185 - 91
   HOOGENBOOM ET AL.: "Methods in Molecular Biology", vol. 248, 2003, HUMAN PRESS, pages: 161 - 175
   MCCAFFERTY ET AL., NATURE, vol. 348, pages 552 - 554
   HOOGENBOOMWINTER, J. MOL. BIOL., vol. 227, 1992, pages 381 - 388
   SIDHU ET AL., J. MOL. BIOL., vol. 340, no. 5, 2004, pages 1073 - 1093
   FELLOUSE, PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 2004, pages 12467 - 12472
   LEE ET AL., J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132
   GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734
   "Genbank", Database accession no. NM_00120; NP
   "NCBI", Database accession no. NP_001288758.1
   "GenBank", Database accession no. AAH02576.1
   VAN RHENEN A ET AL., BLOOD, vol. 107, pages 1459 - 67
   MARSHALL AS ET AL., EUR. J. IMMUNOL., vol. 36, pages 2159 - 69
   BAKKER AB ET AL., CANCER RES., vol. 64, pages 8443 - 50
   MARSHALL AS ET AL., J. BIOL. CHEM., vol. 279, pages 14792 - 80
   "ProtKB/SwissProt", Database accession no. P56159.2
   "SwissProt", Database accession no. Q9UIK5
   "UniProtKB/Swiss-Prot", Database accession no. P15941.3
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.